Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax recently entered into a lucrative, multitiered deal with Sanofi. The agreement helps improve Novavax's prospects.

This Stock Just More Than Doubled in 1 Day: Is It a Buy?

Novavax reached a deal with Sanofi recently which sent the stock soaring. The company now expects to generate up to $1.2 billion in revenue this year.

Is Novavax Stock a Buy?

The stock price of Novavax (NASDAQ: NVAX), a Covid-19 vaccine developer, trades at $13 per share, about 96% below its peak level of $320 seen in February 2021. NVAX stock was trading at around $51 in early June 2022, just before the Fed started increasing rates, and is now 75% below that level, compared to a substantial 40% gain for the S&P 500 during this period.

Up 3x In A Week Will Novavax Stock Continue To See Higher Levels?

Moderna's sales soared into the billions as it conquered the coronavirus vaccine market -- and today the company promises to deliver many new products in the near term. Novavax struggled in recent times, but it's alliance with a vaccine market giant could turn things around.

Could Novavax Become the Next Moderna?

NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Novavax, Inc. (NASDAQ:NVAX). The settlement provides for a fund of $47,000,000 to benefit class members.

Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement

Shopify

Target

The S&P 500 is on the longest streak since February, partly buoyed by stocks with analyst upgrades. The Dow Jones Industrial Average is also increasing amid mixed economic signals, as consumer sentiment dropped to a six-month low due to heightened short-term inflation expectations.

Analyst Upgrades: 3 Stocks Getting the Nod From Pros Last Week

The vaccine developer's shares got a hefty pop on the announcement of a collaboration deal. In the mind of one pundit tracking the stock, however, this means the shares are now fairly valued, and might even fall in price.

1 Wall Street Analyst Thinks Novavax Stock Is Going to $10. Is It a Sell?

Catalyst Pharmaceuticals

Growth stocks have been steadily marching higher since the 2008 financial crisis. Even so, there are still plenty of compelling bargains in the space.

2 Incredible Growth Stocks to Buy Hand Over Fist Right Now

Novavax just eliminated its biggest risk thanks to a billion-dollar deal with pharma giant Sanofi. The agreement could also boost long-term growth.

Novavax Stock Just Tripled. Is It Too Late to Buy?

Novavax stock nearly tripled over two days in May after inking a commercialization deal with Sanofi. Is NVAX stock a buy right now?

Is Novavax Stock A Buy After Nearly Tripling On $1.3 Billion Sanofi Deal?

Actinium Pharmaceuticals

Vertex Pharmaceuticals

The biotech industry is notably risky, but can produce stocks that see massive gains within a day. How can this happen?

3 Cheap Biotech Stocks to Buy Now: May 2024

Koss

Plug Power

Reddit Inc

VinFast Auto Ltd

No, it's not 2021. But waking up today, you might have been forgiven for thinking so.

5 Meme Stocks With a High Short Interest

GameStop

Lucid Group

Meme stocks have the potential to completely change the portfolio health even with a limited exposure of 5% to 10%. The best example now is Carvana (NYSE: CVNA ), which surged from under-$5 levels at the beginning of 2023 to $117.

3 Meme Stocks That Are Likely to Crater in 2024

Novavax stock more than doubled in response to a licensing deal with a big pharma partner. Sanofi will give Novavax $500 million up front to co-license and co-commercialize its COVID-19 vaccine.

Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?

GAITHERSBURG, Md. , May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.

Novavax to Participate in BofA Securities 2024 Health Care Conference

Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.

Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal

Sanofi

Novavax said the deal with Sanofi allows it to remove its "going concern" warning, which it first issued last year due to doubts about staying afloat.

Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker

Tesla

Monday's market action tells us that meme stocks are back in play. However, because not all meme stocks are created equally, investors should focus on those with fundamental catalysts.

Meme Mania is Back: Buy these 3 Stocks

In conjunction with its quarterly report, Novavax announced a pivotal new partnership with Sanofi. Novavax's revenue increased and its losses shrank in Q1.

Novavax's Q1 Results Are Overshadowed by Its Sanofi Partnership

Novavax announced Q1 2024 results with a beat on EPS and a miss on revenue, causing a surge in premarket trading. Novavax finalized a licensing agreement with Sanofi worth up to $1.2B, boosting its COVID-19 vaccine commercial performance. The Sanofi deal revitalizes the outlook for Novavax, providing immediate cash infusion, long-term revenue streams, and a narrowed focus.

Novavax: Sanofi Partnership Revitalizes My Magnum Opus

Novavax, Inc. (NASDAQ:NVAX ) Q1 2024 Earnings Conference Call May 10, 2024 8:30 AM ET Company Participants Erika Schultz - Senior Director of Investor Relations John Jacobs - President and Chief Executive Officer James Kelly - Chief Financial Officer and Treasurer John Trizzino - President and Chief Operating Officer Filip Dubovsky - President of Research and Development Conference Call Participants Roger Song - Jefferies Eric Joseph - JPMorgan Mayank Mamtani - B. Riley Securities Brendan Smith - TD Cowen Vernon Bernardino - H.C.

Novavax, Inc. (NVAX) Q1 2024 Earnings Call Transcript

The pharmaceutical company saw measurable but modest growth last quarter, but remains in the red. Its vaccine science, however, has motivated a rival drugmaker to enter into a lucrative partnership.

Why Novavax Stock More Than Doubled Today

Novavax (NASDAQ: NVAX ) stock investors are celebrating on Friday as the vaccine company's shares hit a new 52-week high after announcing a deal with Sanofi (NASDAQ: SNY ). This saw shares of NVAX stock climb as high as $9.22 per share during normal trading hours on Friday.

NVAX Stock Alert: Novavax Just Hit a New 52-Week High

Novavax (NASDAQ: NVAX ) stock has more than doubled today and is up more than 120% at the time of this writing. This morning, the company announced a co-exclusive licensing agreement with Sanofi (NASDAQ: SNY ) to commercialize its Covid-19 vaccine.

Novavax Sheds Going Concern Warning as NVAX Stock Pops on Sanofi Licensing Deal

Novavax, Inc. (NASDAQ:NVAX) shares surged Friday following the announcement of a significant licensing agreement with Sanofi SA (ADR) (NYSE:SNY), valued at $1.2 billion. The deal encompasses the commercialization of a combined COVID-19 and flu shot, marking a pivotal development in the field of vaccine production.

News for Novavax Stock (NVAX)